Cargando…
Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia
Pediatric acute myeloid leukemia (AML) represents 20% of total childhood leukemia diagnoses and is characterized by poor prognosis with a long-term survival rate around the 50%, when patients are properly treated. The standard treatment for pediatric AML currently consists in a combination of cytara...
Autores principales: | Argenziano, Maura, Tortora, Chiara, Paola, Alessandra Di, Pota, Elvira, Martino, Martina Di, Pinto, Daniela Di, Leva, Caterina Di, Rossi, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274721/ https://www.ncbi.nlm.nih.gov/pubmed/34262648 http://dx.doi.org/10.18632/oncotarget.28000 |
Ejemplares similares
-
Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells
por: Di Paola, Alessandra, et al.
Publicado: (2021) -
Osteosarcoma in Children: Not Only Chemotherapy
por: Argenziano, Maura, et al.
Publicado: (2021) -
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018) -
Biological Aspects of Inflamm-Aging in Childhood Cancer Survivors
por: Rossi, Francesca, et al.
Publicado: (2021) -
Emerging Roles of the Iron Chelators in Inflammation
por: Di Paola, Alessandra, et al.
Publicado: (2022)